FILANA THERAPEUTICS, INC.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX, 78731
Mailing Address
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX, 78731
Phone
512-501-2444
Fiscal Year End
1231
EIN
911911336
Financial Overview
FY2025
$43.95M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 12, 2026 | View on SEC |
| 8-K Current report of material events | March 12, 2026 | View on SEC |
| 8-K Current report of material events | March 10, 2026 | View on SEC |
| 8-K Current report of material events | February 19, 2026 | View on SEC |
| 8-K Current report of material events | December 23, 2025 | View on SEC |
| 8-K/A Current report amendment | December 22, 2025 | View on SEC |
| 8-K Current report of material events | December 18, 2025 | View on SEC |
| 8-K Current report of material events | December 17, 2025 | View on SEC |
| 424B2 Prospectus for shelf offering | December 5, 2025 | View on SEC |
| 8-K Current report of material events | December 3, 2025 | View on SEC |
Annual Reports
10-K
March 12, 2026
- FILANA THERAPEUTICS, INC. focuses on discovering, developing, and commercializing novel therapeutic treatments, with Simufilam as its lead investigational drug candidate.
- The company entered into a license agreement with Yale University during fiscal year 2025.
Material Events
8-K
Strategy Change
March 12, 2026
High Impact
- Filana Therapeutics has officially abandoned its entire Alzheimer's disease drug program.
- Its new lead drug, `simufilam` for `TSC-related epilepsy`, is now under a 'clinical hold' by the FDA.
8-K
Legal Issue
February 19, 2026
High Impact
- U.S. Department of Justice (DOJ) officially closed its investigation into allegations of research misconduct against Cassava Sciences Inc.
- The closure clears the company of specific allegations, indicating they lacked substantiation, and lifts a significant legal and reputational cloud.
8-K
Legal Issue
December 23, 2025
High Impact
- Cassava Sciences Inc. settled a major class-action lawsuit for $31.25 million, resolving claims of violating federal securities laws.
- The settlement removes a significant legal cloud and uncertainty that had been hanging over the company.
8-K
Legal Issue
December 18, 2025
High Impact
- The U.S. Food and Drug Administration (FDA) has placed a "full clinical hold" on Cassava Sciences' planned study for simufilam for Tuberous Sclerosis Complex (TSC)-related epilepsy.
- The FDA requires Cassava Sciences to provide more information, including additional lab data, and to change the planned study design before it can proceed.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.